Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1
- 31 August 2008
- journal article
- research article
- Published by Elsevier BV in Schizophrenia Research
- Vol. 103 (1-3), 104-109
- https://doi.org/10.1016/j.schres.2008.04.023
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Mental Health (01MH90001)
This publication has 15 references indexed in Scilit:
- Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1Schizophrenia Research, 2008
- Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in WomenJama-Journal Of The American Medical Association, 2007
- Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and WomenJama-Journal Of The American Medical Association, 2007
- Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES IIISchizophrenia Research, 2005
- A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controlsSchizophrenia Research, 2005
- Effectiveness of Antipsychotic Drugs in Patients with Chronic SchizophreniaNew England Journal of Medicine, 2005
- The effects of antipsychotic therapy on serum lipids: a comprehensive reviewSchizophrenia Research, 2004
- Consensus Statement: Consensus Development Conference on Antipsychotic Drugs and Obesity and DiabetesBritish Journal of Psychology, 2004
- Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart DiseaseArchives of Internal Medicine, 2003
- Triglyceride Concentration and Ischemic Heart DiseaseCirculation, 1998